Pfizer has taken an early leadership position in creating a discipline around Clinical Innovation, ensuring we are taking advantage of cutting-edge tools, approaches and partnerships to ensure our high-quality clinical trials are conducted with speed and agility. Pfizer’s Clinical Innovation vision centers on making research participation easy for patients and healthcare providers. Our investments and initiatives are focused on three core domains:
- Patient engagement
- Making work easy for sites
- Leveraging real world data
These initiatives are enhanced through our participation in key industry collaborations, such as TransCelerate BioPharma, and others seeking to improve the clinical trial process.
About TransCelerate Biopharma
Pfizer is a founding member of TransCelerate BioPharma Inc., a non-profit organization focused on advancing innovation in research and development (R&D), identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering higher quality medicines to patients. Joining us in the initiative are AbbVie, Astellas, AstraZeneca, Biogen Idec, Boehringer Ingelheim, Braeburn Pharmaceuticals, Bristol-Myers Squibb, Cubist Pharmaceuticals, Eli Lilly, EMD Serono, Forest Laboratories, GlaxoSmithKline, Johnson & Johnson, Onyx Pharmaceuticals, Roche, Sanofi and UCB.
This cross-industry initiative is dedicated to bringing innovative new medicines to the public more quickly. The five initial projects are: development of a shared user interface for investigator site portals; mutual recognition of study site qualification and training; development of risk-based site monitoring approach and standards; development of clinical data standards; and establishment of a comparator drug supply model. In November 2013, TransCelerate announced expansion of the comparator network and site qualification & training project, as well as three new global initiatives — creation of common clinical trial protocol templates, development of clinical trial networks for pediatric and minority populations, and establishment of a global investigator registry.